Familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease type 2 (MCKD2) are autosomal dominant disorders characterized by juvenile hyperuricemia of the underexcretion type, juvenile gout and chronic renal failure in the adult. FJHN/MCKD2 constitute diseases caused by mutations of the human uromodulin (UMOD) gene that encodes uromodulin, the most abundant glycoprotein in normal human urine. The mutations affect the transport of uromodulin, resulting in the accumulation of uromodulin in the kidneys of FJHN/MCKD2 patients. The purpose of this study was to confirm the accumulation of uromodulin in the kidneys of transgenic mice harboring the mutant human UMOD gene with mouse UMOD gene promoter, and to determine the relationship between its accumulation and the effect on uromodulin transport. The mutant human UMOD mRNA and its protein were expressed in the kidneys of transgenic mice. Moreover, the staining of human uromodulin was colocalized with that of mouse uromodulin. Although the human UMOD mRNA levels increased, the protein levels did not change and the accumulation of human uromodulin was not observed. However, the mouse uromodulin consists of two forms, 103 and 117 kDa, and the 103 kDa protein was gradually increased in the kidneys of transgenic mice. Human and mouse uromodulins in the kidneys of transgenic mice were mainly detected in the Triton X-100 insoluble microsomal fraction. Therefore, the progressive accumulation of uromodulin was observed in the plasma membrane of the kidneys of transgenic mice but the accumulated uromodulin protein was not that encoded by the transgene.
Hereditary renal diseases such as familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease type 2 (MCKD2) are autosomal dominant disorders characterized by hyperuricemia of underexcretion type, gout and chronic interstitial nephritis. 1, 2) Onset of hyperuricemia and gout is observed in adolescence and renal insufficiency is usually recognized in adulthood and leads to progressive renal failure.
3) Hart et al. reported that these renal diseases are caused by mutations of the uromodulin (UMOD) gene which encodes for uromodulin. 4) Mutations of the UMOD gene that have been identified are missense and deletion mutations. 3) Moreover, most of the mutant regions are comprised of cysteine residues that affect the disulfide bond, which is important for maintaining the structure of the uromodulin molecule. 5, 6) Uromodulin/Tamm-Horsfall glycoprotein (THP) is the most abundant glycoprotein in normal human urine 7) and found in the epithelial cells of the thick ascending limb (TAL) of Henle's loop and in the early distal convoluted tubule except the macula densa. 8, 9) Moreover, uromodulin is a glycosylphosphatidylinositol (GPI)-anchored membrane protein 10) and the addition of the GPI-anchor is important for uromodulin export from the endoplasmic reticulum (ER) to the plasma membrane of TAL cells. 11) Finally, uromodulin is released into the urine from the plasma membrane by a proteolytic cleavage. 12) On the other hand, uromodulin which included the cysteine-associated missense mutation is delayed for export to the plasma membrane by being retained in the ER in transiently transfected HEK293 cells. 13) It has been reported that mutation of uromodulin leads to the development of clinical features of FJHN/MCKD2 patients, such as the aggregation of uromodulin in the TAL cells and its decreased urinary excretion irrespective of gender, age or renal function. 3, 14, 15) However, the relationship between mutation of uromodulin and disturbance of the uromodulin transport has not been clearly established. For this reason, the present studies were undertaken in which transgenic (Tg) mice were produced harboring the mutant human uromodulin gene (C148W). The aim was (1) to determine whether the kidneys of these Tg mice showed an accumulation of the uromodulin protein, and (2) to study the relationship between the accumulation of uromodulin and disturbance of uromodulin transport.
MATERIALS AND METHODS

Animals
Human UMOD cDNA was amplified by the polymerase chain reaction (PCR) from the reverse transcription (RT) product of human kidney poly (A) ϩ RNA using a sense primer (5Ј-TCTAGACCTGAAGTAGCGGGAAGAG-CAGAAAGGATGGGG-3Ј) and an anti-sense primer (5Ј-ACTGAAAAGTCAGGGTCAAGGTGGCCGAGAGAAG-CAGAG-3Ј). T444G mutation was incorporated into human UMOD cDNA by QuikChange ® II Site-Directed Mutagenesis kit (Stratagene, CA, U.S.A.) using a pair of mutation primers (5Ј-GGATGGATGGCACTGGGAGTGCTCCCCG-GG-3Ј and its complement). Mouse-tail genomic DNA was used as a template for PCR amplification of mouse UMOD promoter cDNA using a sense primer (5Ј-ATATTCAGTTTC-CTCGTTCCTGGCTGGCTTCCTGGGGTG-3Ј) and an antisense primer (5Ј-ATCCTTTACACTCTGCCCTCTGTCCT-GGAAACACCTGCC-3Ј). The DNA fragment of the mouse UMOD promoter was ligated upstream into the T444G mutated human UMOD cDNA containing pcDNA3.1(ϩ) vector (Fig. 1A) .
The authenticity of the 5587 bp mouse UMOD promoter-enhanced T444G human UMOD chimeric gene was verified by DNA sequencing and excised en bloc by Afl II/Dra III digestion, gel-purified, and microinjected into fertilized eggs of C57/BL6 inbred mice for Tg mouse production by the YS institute Inc. (Tochigi, Japan). Tg mice harboring mutant human UMOD and Wild-type (WT) mice were genotyped from genomic DNA extracted from their tails using Wizard Genomic DNA Purification Kit (Promega K.K., Tokyo, Japan), and PCR amplified using a pair of primers corresponding to mutant human UMOD cDNA (sense: 5Ј-CGGGACTGGGTGTCTGTAGT-3Ј; antisense: 5Ј-GTAGGGCTGCGTGTAGGAAG-3Ј). Male WT and Tg mice were placed into metabolic cages for 48 h to obtain daily urine samples at 12, 24 and 36 weeks. The animals were anesthetized by intraperitoneal injections of 50 mg/kg pentobarbital and serum samples and kidneys were obtained. The right kidneys were excised for samples for PCR and Western blotting, while the left kidneys were taken for immunofluorescence. All animal experiments were carried out in accordance with Kyoritsu University of Pharmacy Guide for the Care and Use of Laboratory Animals.
RT-PCR Total RNA was extracted from half of the right kidney using ISOGEN kit (Nippon Gene Co., Ltd., Tokyo, Japan) and contaminating DNA removed from the RNA preparation using DNA-free TM kit (Ambion K.K., Tokyo, Japan). The total RNA was reverse-transcribed and PCR amplified using a pair of primers corresponding to mouse UMOD cDNA (sense: 5Ј-CTGGATGCTGCTGGTAATGA-3Ј; anti-sense: 5Ј-GGGGTAGCACACTCATCCAT-3Ј) and mutant human UMOD cDNA as described above.
Immunofluorescence Frozen sections of 5 mm thickness were prepared from the kidneys of WT and Tg mice and fixed in 4% paraformaldehyde for 15 min at room temperature and in 100% methanol for 10 min at Ϫ20°C. The sections were blocked with phosphate-buffered saline (PBS) containing 2% bovine serum albumin (2% BSA-PBS) for 2 h at room temperature and stained overnight at 4°C with antihuman uromodulin antibody (1 : 50; rabbit anti-human THP polyclonal antibody, Santa Cruz Biotechnology, Inc., CA, U.S.A.) and anti-mouse uromodulin antibody (1 : 50; goat anti-mouse THP polyclonal antibody, Santa Cruz Biotechnology, Inc.) in 0.5% BSA-PBS, followed by treatment with the Qdot ® 565 Goat F(abЈ)2 anti-Rabbit IgG (HϩL) Conjugate (1:100; Invitrogen K.K., Tokyo, Japan) and Qdot ® 655 Rabbit F(abЈ)2 anti-Goat IgG (HϩL) Conjugate (1 : 100; Invitrogen K.K.) in 0.5% BSA-PBS.
Real-Time PCR Total RNA was extracted by the method described above and purified with RNeasy ® Plus Mini kit (QIAGEN K.K., Tokyo, Japan). One microgram of total RNA was reverse-transcribed using TaqMan ® Reverse Transcription Reagents (Applied Biosystems Japan, Tokyo, Japan) and real-time PCR amplified using TaqMan ® Universal PCR Master Mix. The real-time PCR analyses were used for TaqMan ® probe corresponding to human or mouse uromodulin and multiplexed with the internal standard gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The detection was performed using Applied Biosystems 7300 Real-Time PCR System.
Western Blotting The microsomal, Triton X-100 soluble and insoluble fractions of kidneys were prepared as described previously.
16) Protein concentrations of samples were determined with a BCA protein assay kit (Pierce Biotechnology, IL, U.S.A.). Urinary proteins were prepared as described previously. 17) For the quantification of renal and urinary uromodulin proteins, the microsomal, Triton X-100 soluble and insoluble fractions (5 mg) and urinary proteins corresponding to 1/15000 of daily excretion were separated with 7.5 or 10% polyacrylamide minigels by the Laemmli method, and semidry blotted on to nitrocellulose filters (Hybond-ECL, GE Healthcare Bio-Science Corp., NJ, U.S.A.). After incubation for 1 h at room temperature in blocking solution (5% blocking agent of the ECL kit, GE Healthcare Bio-Science Corp., in the PBS with 0.02% Tween 20), the filters were stained overnight at 4°C using anti-human uromodulin antibody (1 : 200, Santa Cruz Biotechnology, Inc.), anti-mouse uromodulin antibody (1 : 400, Santa Cruz Biotechnology, Inc., CA, U.S.A.) or mouse anti claudin-2 18) antibody (1 : 700; Zymed Laboratories Inc., CA, U.S.A.) in the PBS-T solution (PBS with 0.1% Tween 20) containing 2% BSA. Mouse anti claudin-2 antibody was used to confirm the equity in protein loading of the microsomal fraction. The detection was performed with an ECL kit according to the manufacturer's instructions (GE Healthcare Bio-Science Corp.). The densities of the bands were analyzed as uromodulin protein levels using Quantity One software ver. 4.3.0 (Bio-Rad Laboratories, Inc., CA, U.S.A.).
Statistical Analyses All data were expressed as the meansϮstandard errors (S.E.M.). Statistical analyses were performed using the unpaired t-test. pϽ0.05 was considered significant.
RESULTS
The transgene was detected in the genome of 19 out of 59 (32%) newly born F0 mice. The breeding ability of these Tg mice was normal. One of these strains was selected by virtue of the fact that human uromodulin was expressed and most strongly detected by immunofluorescence in the kidney. Tg mice were maintained by breeding male Tg and female nonTg mice, and male non-Tg littermates were used as WT mice.
To ascertain the expression of human UMOD mRNA in the kidney of Tg mice, RT-PCR amplification used a pair of primers corresponding to human or mouse UMOD cDNA (Fig. 1B) . The PCR products of mouse UMOD (197 bp) were detected in the kidneys of WT and Tg mice ( Fig. 1B; lanes 2  and 4) , while the PCR product of human UMOD (294 bp) was detected in the kidney of Tg mice ( Fig. 1B; lane 3) . Moreover, Western blot analyses of the kidneys of WT and Tg mice confirmed the expression of human uromodulin protein in the kidneys of Tg mice. The 93 kDa band of human uromodulin protein was detected in the microsomal fraction of the kidney of Tg mice and was absent in that of the WT mice (Fig. 1C) . However, the band was not detected in the cytosol fraction of the kidneys of WT and Tg mice. Therefore, the human UMOD mRNA and uromodulin protein were expressed in the kidneys of Tg mice.
In addition, immunofluorescence staining for human and mouse uromodulin in the kidneys of WT and Tg mice were performed to confirm the localization of human uromodulin (Fig. 2) . The staining for mouse uromodulin (red fluorescence) was expressed in the kidneys of WT and Tg mice, while the staining for human uromodulin (green fluorescence) was expressed in the kidney of Tg mice. Immunofluorescence studies also showed that human uromodulin was expressed in the kidneys of Tg mice. Moreover, human and mouse uromodulin were both detected in the same region of Tg mouse kidneys. Therefore, human uromodulin was also expressed in the TAL cells that expressed intrinsic mouse uromodulin. 8, 9) Quantitative real-time PCR using the probe for human UMOD and Western blot using anti-human uromodulin antibody were used to study the levels of human UMOD mRNA and uromodulin protein between 12, 24, and 36 week-old Tg mice (Fig. 3 ). The human UMOD mRNA level in 36 weekold Tg mice was 121.6Ϯ5.49% as compared to 100.0Ϯ 5.06% (pϽ0.05) in 12 week-old mice. The human UMOD mRNA was not detected in the kidney of WT mice. There was no difference in the human uromodulin protein levels between 12 and 24 or 12 and 36 week-old Tg mice. Thus, 36 week-old Tg mice had higher human UMOD mRNA levels than 12 week-old Tg mice, but the human uromodulin protein levels in the Tg mice showed no differences among the three age groups.
Quantitative real-time PCR using the probe for mouse UMOD and Western blot using anti-mouse uromodulin anti- Localization of human uromodulin in the kidneys of Tg mice was assessed by double staining using antibodies to human and mouse uromodulins. The frozen sections were stained overnight at 4°C with anti-human and anti-mouse uromodulin antibodies, followed by treatment with the Qdot ® 565 Goat anti-Rabbit IgG Conjugate and Qdot ® 655 Rabbit anti-Goat IgG Conjugate. The staining of mouse uromodulin was detected in the kidneys of WT and Tg mice. The staining of human uromodulin was also detected in the kidneys of Tg mice but not in WT mice. Human and mouse uromodulin showed the same staining patterns in Tg mice and therefore were colocalized. Magnification: ϫ400.
body were performed to study the levels of mouse UMOD mRNA and uromodulin protein between WT and Tg mice at 12, 24 and 36 weeks (Fig. 4) . There was no difference in the mouse UMOD mRNA levels between WT and Tg mice at 12, 24 and 36 weeks. As shown in Fig. 4B (lanes 1 to 6) , two bands (103, 117 kDa) were detected for mouse uromodulin in WT and Tg mice. This indicated that the molecular weights of the mouse uromodulin differed from the 93 kDa human uromodulin expressed in the kidneys of Tg mice (lane 7). The 103 and 117 kDa protein levels of mouse uromodulin in the kidneys of WT and Tg mice are shown in Fig. 4B and their levels between WT and Tg mice are compared in Figs. 4C and 4D, respectively. There was no difference in the 117 kDa protein levels of mouse uromodulin between WT and Tg mice at 12, 24 and 36 weeks. However, the 103 kDa protein levels of Tg mice were different: 253.7Ϯ47.73% for Tg mice as compared to 100.0Ϯ15.81% for WT mice at 36 weeks (pϽ0.05). Moreover, there was no difference in the amounts of urinary uromodulin between WT and Tg mice at 12, 24 and 36 weeks (159.8Ϯ43.65% in Tg mice versus 100.0Ϯ 34.52% in WT mice at 12 weeks; 162.5Ϯ24.82% in Tg mice versus 100.0Ϯ15.52% in WT mice at 24 weeks; and 132.5Ϯ 40.76% in Tg mice versus 100.0Ϯ34.11% in WT mice at 36 weeks). Therefore, the 103 kDa protein levels of mouse uromodulin in the kidneys of Tg mice were higher than in WT mice at 36 weeks and indicated that the protein was accumulated in the kidney.
The microsomal fraction of the kidneys of WT and Tg mice were extracted with Triton X-100 at 4°C, and subjected to Western blot analyses to determine the localization of human and mouse uromodulin proteins. As shown in Fig.  5A , the 93 kDa human uromodulin was expressed in the Triton X-100 soluble and insoluble fractions of the kidney of Tg mice but mainly in the insoluble fraction. The 103 and 117 kDa mouse uromodulins in the kidneys of WT and Tg mice are shown in Fig. 5B . The 117 kDa mouse uromodulin was expressed in the Triton X-100 soluble and insoluble fractions of the kidneys of WT and Tg mice but was strongest in the insoluble fractions. The 103 kDa mouse uromodulin was expressed weakly in the Triton X-100 soluble fractions of the kidneys of WT and Tg mice. The 103 kDa mouse uromodulin was also weakly expressed in the insoluble fraction of WT mice kidneys, but showed a strong expression in the insoluble fraction of Tg mice kidneys. Therefore, human and mouse uromodulin protein were segregated from the plasma membrane of the kidneys of Tg mice.
DISCUSSION
We produced Tg mice harboring the mutant human UMOD gene to demonstrate the mechanism of accumulation of uromodulin in the kidneys of FJHN/MCKD2 patients with UMOD gene mutations. Since FJHN/MCKD2 represents an autosomal dominant disorder and most subjects are heterozygous with the homozygous patient being a rarity, 19) heterozygous Tg mice were used in this study. However, further investigation is needed using homozygous Tg mice because homozygous patients exhibit an earlier onset of hyperuricemia and renal insufficiency than heterozygous patients for the same mutation. 19 gene including mouse UMOD promoter was localized in the TAL cells that expressed intrinsic mouse uromodulin 8, 9) using the transgenic mouse approach 20) and the transgene constructed in this study (Fig. 1A) was including the mouse UMOD gene promoter, the mutant human uromodulin expressed in the kidneys of Tg mice was localized in the TAL cells. Moreover, it is suggested that the localization of mutant human uromodulin is similar to that of uromodulin in the kidneys of FJHN/MCKD2 patients because the staining of mutant human uromodulin was colocalized with that of mouse uromodulin in the kidneys of Tg mice (Fig. 2) .
Since the accumulation of uromodulin is observed in the kidneys of FJHN/MCKD2 patients with UMOD gene mutations, 2) our study sought to ascertain whether an accumulation of extrinsic human uromodulin in the kidneys of Tg mice could be detected due to a mutation of the uromodulin gene. Although the human UMOD mRNA levels increased, its protein levels did not change and the accumulation of human uromodulin was not observed. The reason may be associated with the unfolded protein response (UPR). The UPR is the cellular signaling pathway to ER stress that the disturbances of the correct protein folding by various conditions such as genetic mutation and oxidative stress lead to the accumulation of unfolded or misfolded proteins in the ER. The UPR includes the induction of molecular chaperones to promote protein folding, the translational attenuation to reduce new protein synthesis and the ER-associated degradation to facilitate misfolded protein degradation. 23) Therefore, there is the possibility that it is associated with the translational attenuation and/or the ER-associated degradation. On the other hand, the 103 kDa protein of mouse uromodulin was gradually accumulated in the kidneys of Tg mice. The uromodulin of lower molecular weight reportedly exists as a precursor form in the ER and the upper one as a mature form in the Golgi apparatus and plasma membrane. 24, 25) Thus, the 103 and 117 kDa proteins of mouse renal uromodulin described in this study may correspond to the precursor and mature forms, respectively. Moreover, uromodulin is a GPIanchored membrane protein and the addition of the GPI anchor is important for the precursor form of uromodulin to be exported from the ER to the plasma membrane of renal cells. 10, 11) Since GPI-anchored protein becomes insoluble by the treatment with the Triton X-100 during transport from the Golgi apparatus to the plasma membrane 26) and use GPI anchor as apical sorting determinants, 27) uromodulin localized in the plasma membrane is not soluble in the Triton X-100 at 4°C. In the kidneys of Tg mice, the mutant human uromodulin and the 103 kDa protein of mouse uromodulin are not expressed in the ER but in the plasma membrane because these proteins were mainly detected in the Triton X-100 insoluble fractions. These results differ from an in vitro study in which the mutant uromodulin was delayed for export to the plasma membrane by being retained in the ER and resulted in the accumulation of uromodulin caused by a disturbance of the addition of the GPI anchor.
11,25) Therefore, we considered that the accumulation of mouse uromodulin was caused by a disturbance of the conversion process of the 103 kDa protein to the 117 kDa protein in the lipid rafts of the plasma membrane. In addition, the mutant human uromodulin colocalized in the lipid rafts may be associated with the disturbance of the conversion process.
Although renal insufficiency in FJHN patients is usually recognized between the ages of 20 and 40 years and leads to progressive renal failure, 28) renal impairment was not observed in Tg mice. 29) Moreover, although the 103 kDa protein of mouse uromodulin was accumulated in the plasma membrane, the amount of urinary mouse uromodulin was not decreased in Tg mice at 36 weeks. Since urinary excretion of wild-type uromodulin is decreased in FJHN/MCKD2 patients with UMOD gene mutations, 3, 15) it is suggested that Tg mice at 36 weeks reflect the preclinical stage of FJHN/ MCKD2 patients. Therefore, the mechanism of intracellular accumulation of uromodulin in FJHN/MCKD2 patients with UMOD gene mutations can be postulated as follows. First, the lower molecular weight of uromodulin is accumulated in the plasma membrane by the mutant uromodulin. Then, the progress in accumulation of uromodulin leads urinary excretion of uromodulin to decrease. Thereafter, uromodulin is accumulated in the ER by the disturbance of the export from the ER to the plasma membrane of TAL cells. Finally, the intracellular accumulation of uromodulin induces apoptosis and results in the progressive renal damage in uromodulin storage disease. 2, 24) However, the efficacy of allopurinol in ameliorating the progressive renal damage of FJHN/MCKD2 patients has been questioned [30] [31] [32] and there is no certain cure for these patients. Conceivably, the prevention of initial stage of FJHN/MCKD2 patients, that the attachment of mutant uromodulin in the plasma membrane of the kidney, may have therapeutic potential.
In summary, it is suggested that uromodulin accumulated in the kidneys of FJHN/MCKD2 patients with UMOD gene mutations is not the mutant type but the wild type because the studies described here have shown the progressive accumulation of uromodulin is not extrinsic human uromodulin but intrinsic mouse uromodulin in the kidneys of Tg mice that also harbors the mutant human UMOD gene.
